Investors sold shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on strength during trading hours on Wednesday after an insider sold shares in the company. $60.88 million flowed into the stock on the tick-up and $95.66 million flowed out of the stock on the tick-down, for a money net flow of $34.78 million out of the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 0th highest net out-flow for the day. Regeneron Pharmaceuticals traded up $0.42 for the day and closed at $456.05Specifically, SVP Robert E. Landry sold 526 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the transaction, the senior vice president now owns 9,099 shares in the company, valued at $4,296,456.81. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 87,968 shares of company stock valued at $41,599,948. Corporate insiders own 10.80% of the company’s stock.

REGN has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Piper Jaffray Companies raised their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a report on Tuesday, June 20th. BMO Capital Markets reaffirmed a “market perform” rating and set a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Leerink Swann reaffirmed an “outperform” rating and set a $493.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, June 13th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $575.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average target price of $487.26.

The stock has a market cap of $48.36 billion, a P/E ratio of 45.75 and a beta of 1.62. The firm has a 50-day moving average price of $460.30 and a 200 day moving average price of $451.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 26.38% and a return on equity of 29.95%. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the prior year, the company posted $2.82 EPS. The company’s revenue was up 21.2% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals Inc will post $14.93 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Alpha Windward LLC increased its position in shares of Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares during the period. Cleararc Capital Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.3% during the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 5 shares during the period. Regentatlantic Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 5 shares during the period. Capital Planning Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 2.1% during the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 12 shares during the period. Finally, Sequoia Financial Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 1.7% during the second quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 12 shares during the period. Institutional investors own 67.95% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Traders Sell Regeneron Pharmaceuticals Inc (REGN) on Strength After Insider Selling” was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at http://www.mareainformativa.com/traders-sell-regeneron-pharmaceuticals-inc-regn-on-strength-after-insider-selling/116556/.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.